ArticleTheranostics2011
Integrin targeted delivery of radiotherapeutics.
Article in Theranostics, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed.
- Cell-Penetrating Peptide-Mediated Biomolecule Transportation in Artificial Lipid Vesicles and Living Cells.Molecules (Basel, Switzerland) · 2024Review
- An overview of current therapeutic strategies for glioblastoma and the role of CD73 as an alternative curative approach.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2022Review
- Peptide-based delivery of therapeutics in cancer treatment.Materials today. Bio · 2022Review
- Nanocarriers for Biomedicine: From Lipid Formulations to Inorganic and Hybrid Nanoparticles.International journal of molecular sciences · 2021Review
- Mesoporous Silica Nanoparticles: Properties and Strategies for Enhancing Clinical Effect.Pharmaceutics · 2021Review
- JFK Is a Hypoxia-Inducible Gene That Functions to Promote Breast Carcinogenesis.Frontiers in cell and developmental biology · 2021Article
- Potential for Nuclear Medicine Therapy for Glioblastoma Treatment.Frontiers in pharmacology · 2019Review
- RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer.Molecular pharmaceutics · 2017Article
- Investigating the Cellular Specificity in Tumors of a Surface-Converting Nanoparticle by Multimodal Imaging.Bioconjugate chemistry · 2017Article
- Heat-induced-radiolabeling and click chemistry: A powerful combination for generating multifunctional nanomaterials.PloS one · 2017Article
- Theragnostic ultrasound using microbubbles in the treatment of prostate cancer.Ultrasonography (Seoul, Korea) · 2016Review
- Article
- First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.Cancer biotherapy & radiopharmaceuticals · 2015Article
- Targeted Mesoporous Iron Oxide Nanoparticles-Encapsulated Perfluorohexane and a Hydrophobic Drug for Deep Tumor Penetration and Therapy.Theranostics · 2015Article
- Anti-tumor effect of integrin targeted (177)Lu-3PRGD2 and combined therapy with Endostar.Theranostics · 2014Article
- Peptides in cancer nanomedicine: drug carriers, targeting ligands and protease substrates.Journal of controlled release : official journal of the Controlled Release Society · 2012Review
- Monitoring Breast Tumor Lung Metastasis by U-SPECT-II/CT with an Integrin α(v)β(3)-Targeted Radiotracer( 99m)Tc-3P-RGD(2).Theranostics · 2012Article
- Integrin Targeted Imaging and Therapy.Theranostics · 2011Article
- Evaluation of In-Labeled Cyclic RGD Peptides: Effects of Peptide and Linker Multiplicity on Their Tumor Uptake, Excretion Kinetics and Metabolic Stability.Theranostics · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Targeted radionuclide therapy, which is based on the selective delivery of a sufficient radiation dose to tumors without significantly affecting normal tissues, is a promising therapeutic approach for the treatment of a wide variety of malignancies. Integrins, a family of cell adhesion molecules, play key roles during tumor angiogenesis and metastasis. Among all the integrins, αvβ3 seems to be the most important in the process of tumor angiogenesis. Integrin αvβ3 is highly expressed on activated endothelial cells, new-born vessels as well as some tumor cells, but is not present in resting endothelial cells and most normal organ systems, making it a suitable target for anti-tumor therapy. In this review, we summarize the current development and applications of antibody-, peptide-, and other ligand-based integrin targeted radiotherapeutics for tumor radiation therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.